Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
161Tb-labeled gastrin analogue
- Development stage
- Unknown
- Lead developer
- Jagiellonian University Medical College
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
161Tb-labeled gastrin analogue is a targeted radioligand therapy being evaluated for the treatment of advanced medullary thyroid cancer (MTC). It consists of a gastrin-derived peptide analogue, likely CP04 (a minigastrin derivative), conjugated to the therapeutic radioisotope terbium-161 (161Tb). The peptide component specifically targets and binds to the cholecystokinin-2 receptor (CCK2R), which is highly overexpressed in medullary thyroid carcinoma cells. Terbium-161 is a lanthanide isotope that provides therapeutic radiation through the emission of beta-minus particles, as well as a high yield of Auger and conversion electrons. This combination of radiation types may offer enhanced therapeutic efficacy, particularly for small tumor clusters and micrometastatic disease, by delivering high linear energy transfer radiation directly to the target cells.
- Other names
- 161Tb-labeled Gastrin AnalogueTerbium-161 labeled gastrin analogueTerbium161 labeled gastrin analogueTerbium 161 labeled gastrin analogue
02
Targets
CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on 161Tb-labeled gastrin analogue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 161Tb-labeled gastrin analogue.